Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV Vaccination of Women in Screening Ages
NCT02837926Phase 4Completed
- Sponsor
- CHU de Reims
- Start
- May 2016
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of human papillomavirus type 16 L1 capsid protein antigen and qHPV vaccine in Cervical Cancer (CC), sponsored by CHU de Reims. Primary endpoint: Number of vaccinated patients at 3 years. Started May 2016; status: completed.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenqHPV vaccine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02837926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837926.